Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Free Cash Flow (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Free Cash Flow for 6 consecutive years, with -$10.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Free Cash Flow rose 41.43% year-over-year to -$10.7 million, compared with a TTM value of -$30.1 million through Sep 2025, up 51.56%, and an annual FY2024 reading of -$28.9 million, up 48.63% over the prior year.
  • Free Cash Flow was -$10.7 million for Q3 2025 at Barinthus Biotherapeutics, up from -$18.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $13.7 million in Q4 2024 and bottomed at -$20.2 million in Q2 2023.
  • Average Free Cash Flow over 5 years is -$9.4 million, with a median of -$10.7 million recorded in 2025.
  • The sharpest move saw Free Cash Flow tumbled 1388.55% in 2021, then skyrocketed 475.16% in 2022.
  • Year by year, Free Cash Flow stood at -$8.4 million in 2021, then increased by 24.37% to -$6.4 million in 2022, then plummeted by 206.3% to -$19.4 million in 2023, then skyrocketed by 170.44% to $13.7 million in 2024, then plummeted by 178.29% to -$10.7 million in 2025.
  • Business Quant data shows Free Cash Flow for BRNS at -$10.7 million in Q3 2025, -$18.1 million in Q2 2025, and -$14.9 million in Q1 2025.